ISTH血小板免疫学小组委员会关于COVID-19疫苗诱导免疫性血栓性血小板减少症(VITT)临床与实验室诊断的建议
全球COVID-19疫苗接种推进中,AstraZeneca ChadOx1 nCov-19疫苗出现罕见但严重的血栓事件,称为VITT。ISTH SSC血小板免疫学小组委员会发布指南,阐述如何识别、诊断和管理VITT患者。VITT在临床和病理上与肝素诱导的血小板减少症相似。
要点
- VITT与肝素诱导的血小板减少症在临床和病理上相似。
- 需识别接种AstraZeneca ChadOx1 nCov-19疫苗后出现的罕见血栓事件。
- ISTH SSC血小板免疫学小组委员会提供VITT诊断和管理指南。
核心结论
- VITT是接种AstraZeneca ChadOx1 nCov-19疫苗后出现的罕见但严重的血栓性事件,临床和病理类似肝素诱导的血小板减少症。
研究设计与样本
- ISTH SSC血小板免疫学小组委员会发布的指南,阐述VITT的识别、诊断和管理。
临床怎么用
- 临床医生应识别接种COVID-19疫苗后出现的VITT,并按ISTH SSC指南进行诊断和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine administration is under way worldwide to combat the current COVID-19 pandemic. The newly developed vaccines are highly effective with minimal adverse effects. Recently, the AstraZeneca ChadOx1 nCov-19 vaccine has raised public alarm with concerns regarding the rare, but serious, development of thrombotic events, now known as vaccine-induced immune thrombotic thrombocytopenia (VITT). These thrombotic events appear similar to heparin-induced thrombocytopenia, both clinically and pathologically. In this manuscript, the ISTH SSC Subcommittee on Platelet Immunology outlines guidelines on how to recognize, diagnose and manage patients with VITT.
引用
- Nazy I, Sachs UJ, Arnold DM, et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021. PMID: 34018298. doi:10.1111/jth.15341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。